Algorithms and working party guidelines

Guidelines algorithms are developed for healthcare professionals working in primary and shared care. They are put together by clinical experts to meet a clinical need that is not currently covered by national guidance. Items may contain pharmaceutical promotional information.

Prescribing combined hormone replacement therapy (HRT) containing dydrogesterone

Commissioned by Viatris

This promotional algorithm has been commissioned and funded by Viatris and developed in partnership with Guidelines. Intended for UK healthcare professionals.
View Femoston^® (estradiol/dydrogesterone) and Femoston^® -conti (estradiol/dydrogesterone) prescribing and adverse event reporting information.
FEM-2021-0238 June 2021

Diabetes and frailty: guidance on the management of older adults with type 2 diabetes

By Strain Down Brown Puttanna and Sinclair

Information intended for UK healthcare professionals only. This summary was developed by Guidelines and Dr Strain, based on the guidance developed by Strain WD et al., with the support of a sponsorship from Novo Nordisk UK.

Managing obesity in primary care

By Development Group—Tahrani Parretti O’Kane Chowhan Ratcliffe and Le Brocq

This management algorithm was developed by a multidisciplinary expert panel: Tahrani et al with the support of an educational grant from Novo Nordisk Limited. Information intended for UK healthcare professionals.

Anticholinergics and cognitive impairment in the treatment of overactive bladder

Commissioned by Contura Ltd

This management algorithm has been commissioned and funded by Contura Ltd and developed in partnership with Guidelines. Information intended for UK healthcare professionals.
View adverse event reporting and prescribing information

REG/2020/224 September 2020

Identifying and managing allergic rhinitis in the asthma population

By Development Group—Scadding Holmes Ryan and Williams

This management algorithm was developed by a multidisciplinary expert panel: Scadding et al with the support of an educational grant from Mylan.

Osteoporotic fracture guideline

By Working party—Cooper Javaid Elliott Stephens Tanna

This guideline was developed by a multidisciplinary expert panel: Cooper C et al with the support of an educational grant from UCB Pharma Ltd.

Inhaler choice guideline

By Development group—Usmani Capstick Saleem Scullion

This management algorithm was developed by a multidisciplinary expert panel: Usmani et al and supported by Chiesi Ltd through the provision of a grant for its production.

Women of child-bearing age with inflammatory rheumatic diseases guideline

By Working party—Giles Allen Nelson-Piercy Tower Warburton Gordon

This guideline was developed by a multidisciplinary expert panel: Giles I et al with the support of an educational grant from UCB Pharma Ltd.

Consensus guideline on the holistic management of patients requiring anticoagulation

By Working party–Fay Antoniou Martins Merriman Patrickson Uprichard

This guideline was developed by a multidisciplinary expert panel: Fay M et al with the support of an educational grant from Bayer plc.

Guideline for the managed introduction of biosimilar basal insulin

By Working party—Down Beba Brown Diggle Goel Milne

This guideline was developed by a multidisciplinary expert panel: Down S et al with the support of an educational grant from Mylan.

Medication management of patients with enteral feeding tubes

By Working party—Wright Griffith Merriman Smithard Smyth Welsh

This guideline was developed by a multidisciplinary expert panel: Wright D et al with the support of a grant from Rosemont Pharmaceuticals Ltd.

Uncomplicated recurrent UTI guideline

By Working party—Rees Brocksom Harding Jacobson Rollinson

This guideline was developed by a multidisciplinary expert panel: Rees J et al with the support of a grant from Aspire Pharma Ltd.

Stable peripheral arterial disease guideline

By Working party—Begg Antoniou Fay Garnham Nuttall

This guideline was developed by a multidisciplinary expert panel: Begg A et al with the support of a grant from Bayer plc.

Stable coronary artery disease guideline

By Working party—Fay Banerjee Begg Bostock-Cox Gordon

This guideline was developed by a multidisciplinary expert panel: Fay M et al with the support of a grant from Bayer plc.

Pancreatic exocrine insufficiency guideline

By Development group: Hambling Cummings Merriman & Widdowson

This management algorithm was developed by a multidisciplinary expert panel: Hambling C et al with the support of a grant from Mylan Ltd.

Swallowing difficulties: management in adults with learning disability

By Working Party—Wright et al.

This guideline was developed by a multidisciplinary expert panel: Wright D et al with the support of an unrestricted grant from Rosemont Pharmaceuticals Ltd.

Use of unlicensed medicines in paediatric patients guideline

By Working Party—Tomlin Cockerill Costello Griffith Hicks Sutcliffe Tuleu Wong Wright

This guideline was developed by a multidisciplinary expert panel: Tomlin  S  et  al with the support of a grant from Rosemont Pharmaceuticals  Ltd.

Swallowing difficulties: medication management guideline

By Working Party—Wright Begent Crawford Foundling-Miah Griffith & Merriman

This guideline was developed by a multidisciplinary expert panel: Wright  D  et  al with the support of a grant from Rosemont Pharmaceuticals  Ltd.

Management of BPH with LUTS guideline

By Development Group: Rees Brocksom Garner & Rochester

This management algorithm was developed by a multidisciplinary expert panel: Rees J et al with the support of a grant from NeoTract, Inc.